SCHEMBL10078752

SCHEMBL10078752

Cc1ccc(C(=O)Nc2ccc(F)c(C(F)(F)F)c2)cc1NC(=O)/C=C/c1cccnc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.54
NAMPT P43490 9/20 0.53
BRAF P15056 3/20 0.52
TEK Q02763 1/20 0.52
EGFR P00533 1/20 0.52
KIT P10721 4/20 0.52
PDGFRA P16234 3/20 0.52
KDR P35968 3/20 0.52
HDAC1 Q13547 1/20 0.51
MEN1 O00255 1/20 0.51
GALR2 O43603 1/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
HPGD P15428 1/20 0.51
RECQL P46063 1/20 0.51
KMT2A Q03164 1/20 0.51
DDR1 Q08345 1/20 0.48
DDR2 Q16832 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2679244 1.00 CSF1R (0.54) CSF1RNAMPTBRAFTEKEGFR
SCHEMBL2679311 0.97 CSF1R (0.54) CSF1RNAMPTBRAFTEKKIT
SCHEMBL10054803 0.97 CSF1R (0.54) CSF1RNAMPTBRAFTEKKIT
SCHEMBL10077755 0.95 CSF1R (0.57) CSF1RNAMPTBRAFEGFRKIT
SCHEMBL2679206 0.95 CSF1R (0.57) CSF1RNAMPTBRAFEGFRKIT
SCHEMBL10054792 0.91 BRAF (0.58) CSF1RNAMPTBRAFEGFRKIT
SCHEMBL2679829 0.91 BRAF (0.58) CSF1RNAMPTBRAFEGFRKIT
SCHEMBL10078410 0.91 BRAF (0.62) CSF1RNAMPTBRAFEGFRKIT
SCHEMBL2679309 0.91 BRAF (0.62) CSF1RNAMPTBRAFEGFRKIT
SCHEMBL2678800 0.90 NAMPT (0.55) NAMPTBRAFKDRMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament ABL1, ABL2, BCR CSF1R 2608/4885NAMPT 3700/4885BRAF 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.